LY2605541 Articles
Lilly and Boehringer adjust LY2605541 deal; announce positive Ph III data for empagliflozin
8 January 2013
More news from American Diabetes Association meeting
13 June 2012
Showing 1-3 of 3 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
